Lupin launches authorised generic version of Antara in US
03 November 2021 | News
Fenofibrate capsules are indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol
Image Credit: Shutterstock
Lupin announced the launch of the authorised generic version of Antara (Fenofibrate) Capsules, 30 mg and 90 mg, of Lupin Atlantis Holdings, SA Corporation, a wholly-owned subsidiary of Lupin.
Fenofibrate capsules are indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (total-c), Triglycerides (TG) and apolipoprotein B (Apo B), and to increase high-density lipoprotein cholesterol (HDL-C) in adult patients with primary hypercholesterolemia.
Fenofibrate Capsules (RLD: Antara4 Capsules) had estimated annual sales of $7 million in the US (IQVIA MAT September 2021).
